The CLOVER-1 study is testing CLR 131 in patients with relapsed or refractory non-Hodgkin lymphoma, including lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
Arjun V. Balar, MD
It's pretty rare to ever see a clinical trial of a novel therapy report a 100% overall response rate in the studied population, which is why the initial data reported at the American Association for Cancer Research malignant lymphoma conference from the CLOVER-1 study, a phase 2 trial of CLR 131, caught my eye (NCT02952508). Sadly, the study reported data from only the 4 initial patients enrolled, but it is still safe to say that this novel agent, a unique blend of radioisotope and drug-conjugate technologies to generate a first-in-class cancer therapeutic, could be something special.
CLR 131 is a proprietary phospholipid ether conjugated to iodine 131, which is a radioisotope previously well established in the treatment of advanced thyroid cancer. The phospholipid ether moiety of CLR 131 is selectively taken up by lipid raft microdomains that are expressed on tumor cells, leading to intracellular accumulation in the cytoplasm and subsequent cancer cell death.
Normal cells, theoretically, do not express the same lipid raft microdomains and thus do not take up CLR 131, limiting off-target toxicity. The CLOVER-1 study is testing this novel agent in patients with relapsed or refractory non-Hodgkin lymphoma, including lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. In an effort to always be fully transparent, as a genitourinary medical oncologist, I admit I do not have expertise in treating patients with these conditions, but my sense is that after commonly used standard agents such as rituximab (Rituxan), ibrutinib (Imbruvica), and/or autologous stem cell transplant, few effective treatment options exist.
Normal cells, theoretically, do not express the same lipid raft microdomains and thus do not take up CLR 131, limiting off-target toxicity. The CLOVER-1 study is testing this novel agent in patients with relapsed or refractory non-Hodgkin lymphoma, including lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. In an effort to always be fully transparent, as a genitourinary medical oncologist, I admit I do not have expertise in treating patients with these conditions, but my sense is that after commonly used standard agents such as rituximab (Rituxan), ibrutinib (Imbruvica), and/or autologous stem cell transplant, few effective treatment options exist.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More